When it comes to the euro, what doesn’t kill it should make it stronger. The existential threat posed to the single currency by the French elections has faded. The focus should move to the economy and the European Central Bank.
Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
Becton Dickinson’s acquisition of C.R. Bard is worth the high price.
U.S. paint giant PPG has sensibly combined its latest offer for European rival Akzo Nobel with a raft of commitments to staff and other local interest groups.
With political risk receding, Europe will look more attractive for investors than it has for some time. How much markets rally in response will be a measure not just of how scared investors were about France, but could reveal what deeper worries remain on the horizon.
High levels of consumer and business confidence don’t jibe with a slow-growing U.S. economy. That can’t last.
The 40%-plus rise in China Evergrande stock over the past month has been built on a share buyback program it can’t afford.
Alcoa’s and Arconic’s big gains following last year’s split will be put to the test when both report earnings this week.
A big shift in flash memory production will drive further gains for Lam Research and Applied Materials.